Compare · AXSM vs MTRI
AXSM vs MTRI
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Mentari Therapeutics Inc. (MTRI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and MTRI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $7.45B, about 7.6x MTRI ($982.3M).
- MTRI has been more active in the news (18 items in the past 4 weeks vs 4 for AXSM).
- AXSM has more recent analyst coverage (25 ratings vs 0 for MTRI).
- Company
- Axsome Therapeutics Inc.
- Mentari Therapeutics Inc.
- Price
- -
- -
- Market cap
- $7.45B
- $982.3M
- 1M return
- -
- +36.94%
- 1Y return
- -
- +3.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 4
- 18
- Recent ratings
- 25
- 0
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Mentari Therapeutics Inc.
The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Latest AXSM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
- Truist resumed coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Chief Operating Officer Jacobson Mark L. sold $2,086,500 worth of shares (10,000 units at $208.65) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $12.95 (SEC Form 4)
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
Latest MTRI
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13D filed by Mentari Therapeutics Inc.
- Officer Seurer Jerad G. was granted 257,000 stock options (SEC Form 4)
- Director Pernice Michelle Patricia was granted 37,000 stock options (SEC Form 4)
- Officer Divis Gregory J was granted 1,560,599 stock options (SEC Form 4)
- Director Bruno Julianne was granted 37,000 stock options (SEC Form 4)
- Officer Hagen Brett R was granted 171,000 stock options (SEC Form 4)
- Director Sandler Laura Lee was granted 37,000 stock options (SEC Form 4)
- Director Shegog Todd was granted 37,000 stock options (SEC Form 4)